DEF 14A: Acadia Pharmaceuticals Outlines Executive Compensation and Governance in 2024 Proxy Statement

Acadia Pharmaceuticals' 2024 proxy statement details executive compensation, board structure, and key proposals for the upcoming annual meeting.

Summary

• Acadia Pharmaceuticals has released its 2024 proxy statement, outlining key proposals for the annual meeting on May 29, 2024.
• The meeting will be held virtually, allowing stockholders to attend online.
• Stockholders will vote on the election of three Class II directors, an advisory vote on executive compensation, approval of the 2024 Equity Incentive Plan, and ratification of Ernst & Young LLP as the independent registered public accounting firm.
• The proxy statement details the compensation of named executive officers, the structure of the Board of Directors, and corporate governance practices.
• The company's Board consists of nine members, with three Class II directors up for election.
• The proxy statement includes information on board diversity, independence, and the role of the board in risk oversight.
• The company's compensation policies are designed to align executive compensation with business objectives and corporate performance.
• The proxy statement also discusses transactions with related persons and other information for stockholders.
• The company is requesting stockholder approval of the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (the 2024 Plan) to increase the number of shares available for the grant of stock options, restricted stock unit awards and other awards, which will enable us to have a competitive equity incentive program to compete with our peer group for key talent.
• If this Proposal 3 is approved by our stockholders, subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the 2024 Plan will not exceed the number resulting from the following: a) 15,350,000 shares, which number is the sum of (i) 7,018,288 new shares plus (ii) 8,331,712 shares of our common stock available for the grant of new awards under the 2010 Plan and the Inducement Plan as of December 31, 2023; less b) (i) one share of our common stock for every one share that was subject to an Appreciation Award (as defined below) granted under the 2010 Plan or the Inducement Plan after December 31, 2023, and prior to the effective date of the 2024 Plan and (ii) 1.49 shares of our common stock for every one share that was subject to a Full Value Award (as defined below) granted under the 2010 Plan or the Inducement Plan after December 31, 2023, and prior to the effective date of the 2024 Plan; plus c) a number of shares of our common stock equal to the Prior Plans Returning Shares (as described below), if any, as such shares become available from time to time.

Sentiment

Score: 7

Explanation: The document is primarily informational, but the positive performance in 2023 and the commitment to corporate social responsibility and DEI contribute to a moderately positive sentiment.

Positives

• The company has a comprehensive compliance program aligned with industry standards.
• Acadia is committed to minimizing its environmental footprint and adhering to environmental regulations.
• The company has a team dedicated to Diversity, Equity, & Inclusion (DEI) strategy and whole-self employee wellbeing.
• The company maintains robust stock ownership guidelines for executive officers and non-employee directors.
• The company has a clawback policy that covers cash and equity incentive awards.
• The company has positive pay practices, including at-risk compensation, measurable goals, and an independent compensation consultant.

Negatives

• The proxy statement notes that only 64% of the say-on-pay vote at the 2023 annual meeting was in favor of the compensation of the Company’s named executive officers in 2022, reflecting stockholder concerns regarding certain retention awards made in the previous year.

Risks

• The proxy statement contains forward-looking statements that involve risks and uncertainties.
• The company's ability to realize the benefit of any tax deductions depends on its generation of taxable income.
• The company's performance goals include highly sensitive competitive data, and disclosure of specific portions of these goals could result in competitive harm.

Future Outlook

The Company believes that it is well-positioned to execute on its long-term objectives, including maximizing the profitability of NUPLAZID and DAYBUE, completing ongoing and planned clinical trials, and continuing to invest in its pipeline through business development.

Industry Context

The proxy statement benchmarks executive compensation against a peer group of biotechnology and pharmaceutical companies.

Comparison to Industry Standards

• The Compensation Committee uses a peer group developed in coordination with an independent compensation consulting firm to assist it in understanding market factors, including the range of base salary, target annual incentive compensation, and equity grant levels offered for comparable roles at comparable companies.
• The Compensation Committee looks to the peer group of companies, as well as the broader market, as a baseline for executive compensation decisions.
• The resulting peer group used for 2023 compensation decisions consisted of: Alkermes, Insmed, Amicus Therapeutics, Intra-Cellular Therapies, Apellis Pharmaceuticals, Ironwood Pharmaceuticals, Biocryst Pharmaceuticals, Nektar Therapeutics, Biohaven Pharmaceuticals, Pacira BioSciences, Blueprint Medicines, PTC Therapeutics, ChemoCentryx, Sage Therapeutics, Corcept Therapheutics, Sorrento Therapeutics, FibroGen, Supernus Pharmaceuticals, Global Blood Therapeutics, Ultragenyx.
• In the fall of 2023, with the assistance of FW Cook, the Compensation Committee approved an updated peer group to be used for 2024 compensation decisions. The following changes were made to the peer group: Axsome Therapeutics, Exelixis, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, and Sarepta Therapeutics were added, and Biohaven Pharmaceuticals, ChemoCentryx, FibroGen, Global Blood, Ironwood Pharmaceuticals, Nektar Therapeutics, and Sorrento Therapeutics were removed.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders are invited to participate in the annual meeting and vote on key proposals.
• Employees are affected by the company's compensation policies and equity incentive plan.
• Customers and patients benefit from the company's commitment to product safety and quality.
• The company's corporate social responsibility initiatives impact communities and the environment.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on May 29, 2024.

Key Dates

Keywords

proxy statement, executive compensation, board of directors, corporate governance, annual meeting, equity incentive plan, stockholders, Acadia Pharmaceuticals